Hepatitis C virus infection elimination — the WHO target of eighty percent reduction in incidence and sixty-five percent reduction in mortality by 2030 — depends on direct-acting antiviral therapy's remarkable cure rates and expanding treatment access, with the Gastrointestinal Therapeutics Market reflecting both the therapeutic success of pangenotypic DAA regimens and the challenges of reaching the estimated fifty to seventy percent of HCV-infected individuals globally who remain undiagnosed and untreated.

Pangenotypic direct-acting antivirals — sofosbuvir/velpatasvir (Epclusa) and glecaprevir/pibrentasvir (Mavyret) — achieve sustained virologic response (functional cure) rates exceeding ninety-five percent for most HCV genotypes in eight to twelve weeks of oral therapy, transforming HCV from a chronic progressive liver disease toward a curable infection in nearly all treated patients. The elimination of interferon-based therapy with its severe side effect burden and only sixty to seventy percent SVR rates has transformed HCV treatment acceptance and completion.

HCV treatment access challenges — remaining in insurance prior authorization requirements, cost barriers in uninsured populations, and the difficulty of reaching incarcerated individuals, injection drug users, and rural populations with concentrated HCV prevalence — prevent the high coverage necessary for population-level elimination. State and federal programs providing DAA access to Medicaid populations and the VA system's near-universal HCV treatment program have demonstrated the achievability of population-level cure rates when access barriers are systematically addressed.

HCV re-infection risk in people who inject drugs — with high re-infection rates from continued injection drug use undermining the elimination impact of individual cures — requires harm reduction integration with HCV treatment programs to prevent re-infection that treatment-without-prevention cannot address.

Do you think the US will achieve WHO HCV elimination targets by 2030, or will access barriers prevent reaching the high coverage rates that mathematical modeling requires for elimination?

FAQ

What is the cure rate for hepatitis C with direct-acting antivirals? Pangenotypic DAA regimens including Epclusa and Mavyret achieve sustained virologic response (functional cure) in ninety-five to ninety-nine percent of treated patients across HCV genotypes in eight to twelve weeks of oral therapy.

What is the challenge for hepatitis C elimination? Despite near-perfect cure rates, an estimated fifty percent or more of HCV-infected individuals globally remain undiagnosed; reaching marginalized populations including people who inject drugs, incarcerated individuals, and rural communities is the primary elimination barrier.

#GastrointestinalTherapeutics #HepatitisCcure #DAA #HCVelimination #SofosbuvirVelpatasvir #HCVtreatment